Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its ...

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the ... The gross proceeds to the Company from this offering are expected to be approximately $7.4 million, before deducting the placement ...

Shares in the NYSE-listed company rose 77% at market open on 24 January 2025, compared to a market close, which occurred shortly after Allurion made the announcement. It is the highest price the ...